Innovent Announces Phase Ib Results of Higher-dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalMedicine ...Middle East

ROCKVILLE, Md. and SUZHOU, China, Oct. 16, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other...

Hence then, the article about innovent announces phase ib results of higher dose mazdutide ibi362 in chinese participants with overweight or obesity published in eclinicalmedicine was published today ( Monday 17/10/2022 - 03:08 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces Phase Ib Results of Higher-dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalMedicine )

Also on site :

• Frustration in Lebanon as Israel expands invasion
• NYT ‘Connections’ Hints, Clues and Answers Today, Saturday, May 30, 2026
• Brandon Lake Is a Double Winner at 2026 K-LOVE Fan Awards: Full Winners List